Providing a diverse range of perspectives from bullish to bearish, 9 analysts have published ratings on Neurocrine Biosciences NBIX in the last three months.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 1 | 5 | 3 | 0 | 0 |
| Last 30D | 0 | 1 | 0 | 0 | 0 |
| 1M Ago | 0 | 2 | 0 | 0 | 0 |
| 2M Ago | 0 | 1 | 0 | 0 | 0 |
| 3M Ago | 1 | 1 | 3 | 0 | 0 |
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $153.78, with a high estimate of $200.00 and a low estimate of $140.00. Marking an increase of 8.39%, the current average surpasses the previous average price target of $141.88.
Analyzing Analyst Ratings: A Detailed Breakdown
A clear picture of Neurocrine Biosciences's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Charles Duncan | Cantor Fitzgerald | Maintains | Overweight | $155.00 | - |
| Anupam Rama | JP Morgan | Raises | Overweight | $158.00 | $148.00 |
| Jay Olson | Oppenheimer | Raises | Outperform | $200.00 | $170.00 |
| Anupam Rama | JP Morgan | Lowers | Overweight | $148.00 | $154.00 |
| David Hoang | Citigroup | Lowers | Neutral | $140.00 | $141.00 |
| Uy Ear | Mizuho | Raises | Neutral | $140.00 | $116.00 |
| Mohit Bansal | Wells Fargo | Raises | Equal-Weight | $140.00 | $127.00 |
| Chris Shibutani | Goldman Sachs | Raises | Buy | $153.00 | $134.00 |
| Carter Gould | Barclays | Raises | Overweight | $150.00 | $145.00 |
Key Insights:
- Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Neurocrine Biosciences. This information offers a snapshot of how analysts perceive the current state of the company.
- Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Neurocrine Biosciences compared to the broader market.
- Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Neurocrine Biosciences's market standing. Stay informed and make well-considered decisions with our Ratings Table.
Stay up to date on Neurocrine Biosciences analyst ratings.
Delving into Neurocrine Biosciences's Background
Neurocrine Biosciences Inc is a research-based pharmaceutical company advancing drug candidates in the central nervous system and endocrine-related categories. The company's three late stage clinical programs are elagolix which is hormone releasing antagonist for women's health, opicapone which is an inhibitor for parkinson's patients, and ingrezza for tourette syndrome.
Neurocrine Biosciences: Financial Performance Dissected
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Neurocrine Biosciences displayed positive results in 3 months. As of 31 December, 2023, the company achieved a solid revenue growth rate of approximately 25.05%. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Neurocrine Biosciences's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of 28.67%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Neurocrine Biosciences's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of 6.98%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): Neurocrine Biosciences's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of 4.84%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: With a below-average debt-to-equity ratio of 0.19, Neurocrine Biosciences adopts a prudent financial strategy, indicating a balanced approach to debt management.
Analyst Ratings: Simplified
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
